These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 20101016)
21. Observational studies and the withdrawal of rofecoxib. Watson DJ; Santanello NC Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998 [No Abstract] [Full Text] [Related]
22. Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. Madigan D; Sigelman DW; Mayer JW; Furberg CD; Avorn J Am Heart J; 2012 Aug; 164(2):186-93. PubMed ID: 22877803 [TBL] [Abstract][Full Text] [Related]
23. Adverse cardiovascular effects of rofecoxib. Nissen SE N Engl J Med; 2006 Jul; 355(2):203-4; author reply 203-5. PubMed ID: 16801355 [No Abstract] [Full Text] [Related]
24. Evaluating drug effects in the post-Vioxx world: there must be a better way. Avorn J Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873 [No Abstract] [Full Text] [Related]
25. International regulatory activity restricting COX-2 inhibitor use and deaths due to gastrointestinal haemorrhage and myocardial infarction. Metcalfe C; Wheeler BW; Gunnell D; Martin RM Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):778-85. PubMed ID: 20680998 [TBL] [Abstract][Full Text] [Related]
26. Some key points emerging from the COX-2 controversy. Urquhart J Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):145-7. PubMed ID: 15654723 [No Abstract] [Full Text] [Related]
27. The Vioxx fallout. Palmer K Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592 [No Abstract] [Full Text] [Related]
28. Rofecoxib, Merck, and the FDA. Villalba L; Witter J N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745 [No Abstract] [Full Text] [Related]
29. Experts call for active surveillance of drug safety. Wadman M Nature; 2007 Mar; 446(7134):358-9. PubMed ID: 17377551 [No Abstract] [Full Text] [Related]
31. Safety, scrutiny and conflicts: assessing the fallout and lessons learned from pharmaceuticals. Lanzafame RJ Photomed Laser Surg; 2005 Feb; 23(1):1-2. PubMed ID: 15782023 [No Abstract] [Full Text] [Related]
32. What ails the FDA? Gorelick KJ N Engl J Med; 2005 Jun; 352(24):2553-4. PubMed ID: 15958814 [No Abstract] [Full Text] [Related]
33. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag". Armstrong D Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016 [No Abstract] [Full Text] [Related]
34. [How many harmed by rofecoxib in Germany?]. Scharnetzky E; Andersohn F; Schill W; Garbe E; Pigeot I Med Klin (Munich); 2006 Aug; 101(8):675-6; author reply 678-9. PubMed ID: 17051670 [No Abstract] [Full Text] [Related]
35. Seeds of doubt--ADVANTAGE no one. Jackson G Int J Clin Pract; 2008 Nov; 62(11):1637. PubMed ID: 19143848 [No Abstract] [Full Text] [Related]
36. The COX-2 inhibitors--an update. Furberg CD Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896 [No Abstract] [Full Text] [Related]
37. More bad news about anti-inflammatory agents. Haller C J Med Toxicol; 2005 Dec; 1(1):36-7. PubMed ID: 18072102 [No Abstract] [Full Text] [Related]